Moderna Is Waiting on Vaccine Orders From U.S.

The transcript covers a discussion with Moderna's CEO, Stephane Bancel, about the company's earnings, guidance, and market perception. It highlights the challenges in securing US government contracts for vaccines, the situation in China regarding vaccine efficacy, and the company's broader platform for drug development. The CEO also addresses the market's view of Moderna as a COVID-19 vaccine company and the strategic decision to conduct stock buybacks.

What is the current book of business value for Moderna as mentioned in the first section?

• $21 billion

• $30 billion

• $15 billion

• $25 billion

Which country has not ordered the Omicron booster from Moderna?

• Japan

• Switzerland

• United States

• Canada

What is the main reason for the market's pessimism about Moderna's future prospects?

• Uncertainty about COVID-19 vaccine sales in 2023 and 2024

• High competition in the pharmaceutical industry

• Decreasing demand for vaccines

• Lack of new vaccine development

How quickly has Moderna been able to move vaccines from phase one to phase three?

• 24 months

• 12 months

• 18 months

• 6 months

What is the market missing about Moderna's platform according to the CEO?

• Its speed and breadth

• Its cost-effectiveness

• Its global reach

• Its technological complexity

What is the CEO's perspective on the stock buybacks?

• They were a mistake

• They will create long-term value

• They were unnecessary

• They were a short-term strategy

What is the CEO's view on the market's appreciation of Moderna's platform?

• The market undervalues it

• The market is indifferent

• The market overvalues it

• The market fully appreciates it